CTKB Cytek Biosciences, Inc.

NASDAQ
$5.83

Cytek Biosciences, Inc. (CTKB) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.04 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.2% since its last earnings release on November 4, 2026.

Cytek Biosciences Beat Consensus Estimates, Narrows Guidance
Wednesday, November 4, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.04)
Rev est $63.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.59

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cytek Biosciences, Inc.

Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.